Ask AI
ProCE Banner Activity

FAQs: An Oncology Nurse’s Perspectives on the Management of Adverse Events Associated With CDK4/6 Inhibitor Use for Patients With HR+/HER2- Breast Cancer

Clinical Thought

In this commentary, an oncology nurse addresses questions regarding optimal approaches for the management of adverse events associated with CDK4/6 inhibitors for patients with HR+/HER2- breast cancer, including ways to address barriers to meeting treatment goals and the importance of using a multidisciplinary team approach to achieve optimal outcomes.

Released: October 16, 2025

Share

Provided by

Provided by Clinical Care Options, LLC.

ProCE Banner

Supporters

Novartis Pharmaceuticals Corporation

Faculty Disclosure

Primary Author

Ashley Martinez, DNP, APRN, FNP-BC, AOCNP, CPHQ, NEA-BC, NPD-BC: consultant/advisor/speaker: Biotheranostics, Curio Science, Lilly.